Alternatives to Draig Therapeutics

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing first-in-class oral therapy for BK polyomavirus infections.

Immunotherapy company targeting oncology and autoimmune diseases.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing novel male contraceptives.

Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Advancing targeted alpha therapies.

A biopharmaceutical company focused on drug discovery and development.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Clinical-stage biotech company developing transformative cytokine therapies.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Accelerating medicine for the people who need it, prescribe it, and create it.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Biotechnology company developing new medicines for Parkinson's disease and other neurological disorders.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Biopharmaceutical company developing and commercializing CNS disease treatments.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Developing novel immunotherapies and diagnostics for cancer.

Developing gene editing therapies to lower cholesterol.

Developing ultrasound-mediated nonviral genetic medicines.

Developing highly targeted, small molecule medicines.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.